https://www.selleckchem.com/pr....oducts/cetuximab.htm
may have coincided with natural disease resolution in some patients. Further effects of the efficacy of spesolimab in PPP are being explored in a phase IIb trial. Multimorbidity, prefrailty, and frailty are frequent in ageing populations, but their independent relationships to long-term prognosis in home-dwelling older people are not well recognised. In the Helsinki Businessmen Study (HBS) men with high socioeconomic status (born 1919-1934, n = 349 have been followed-up from midlife. In 2000, multimorbidity (≥ 2 conditions), phenoty
Like
Comment
Share
